Corticosteroids Clinical Scenarios Quiz

In Addison's disease, the adrenal glands do not produce sufficient hormones, particularly cortisol and aldosterone. Hydrocortisone serves as a replacement for cortisol, while fludrocortisone replaces aldosterone, which helps regulate sodium and potassium levels and maintain blood pressure. This combination effectively addresses both aspects of adrenal insufficiency, ensuring adequate hormone levels and preventing complications associated with the disease. Other options either lack the necessary components or do not provide a complete replacement therapy for the hormonal deficiencies present in Addison's disease.

Dexamethasone, a corticosteroid, affects glucose metabolism by stimulating gluconeogenesis in the liver, which increases the production of glucose. Simultaneously, it impairs the uptake and utilization of glucose by peripheral tissues, such as muscle and fat, leading to elevated blood glucose levels. This mechanism is particularly significant in patients with diabetes, as their ability to manage glucose levels is already compromised. Consequently, the combined effect of increased glucose production and decreased utilization results in hyperglycemia, especially in individuals who were previously well-controlled.

Topical corticosteroids are anti-inflammatory agents that can reduce redness and swelling in skin lesions. However, they also suppress the local immune response, which is crucial for combating fungal infections. By diminishing the immune system's ability to fight the fungus, corticosteroids can exacerbate the infection rather than facilitate healing. Therefore, using corticosteroids in the presence of a fungal infection is not clinically suitable, as it may lead to further complications and prolonged infection.

Betamethasone is a corticosteroid that promotes fetal lung maturation by stimulating surfactant production in the alveoli, which is crucial for reducing the risk of respiratory distress syndrome in premature infants. Administering it intramuscularly allows for effective absorption and rapid action, enhancing its effectiveness in accelerating lung development before delivery. This intervention is particularly important for infants born before 34 weeks of gestation, as their lungs are often underdeveloped.

Long-term corticosteroid therapy can suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency if the medication is stopped abruptly. Tapering off the corticosteroids gradually allows the adrenal glands and the anterior pituitary to resume normal function and hormone production, reducing the risk of withdrawal symptoms and adrenal crisis. This approach is essential for patient safety and helps prevent complications associated with sudden cessation of corticosteroid therapy.

In patients with liver dysfunction, the metabolism of certain medications can be significantly impaired. Prednisone, a commonly used corticosteroid, is a prodrug that needs to be converted in the liver to its active form, prednisolone. In individuals with hepatic impairment, this conversion may be compromised, leading to reduced effectiveness of the drug. Therefore, careful consideration of the patient's liver function is crucial when prescribing corticosteroids, as using prednisone in such cases may not provide the desired therapeutic effect.

Long-term corticosteroid therapy can lead to decreased bone density due to its effects on calcium absorption and bone metabolism. Prescribing calcium and vitamin D supplements helps mitigate these effects by promoting bone health and preventing further bone loss. Monitoring the patient is crucial to assess the effectiveness of this intervention and make necessary adjustments. Discontinuing corticosteroids or switching to a mineralocorticoid may not be feasible or effective, while increasing the corticosteroid dose would likely worsen bone density issues. Thus, supplementation and monitoring is the most appropriate management strategy.

Betamethasone is a synthetic glucocorticoid commonly used in the diagnosis of Cushing's syndrome due to its potency and effectiveness in suppressing the hypothalamic-pituitary-adrenal (HPA) axis. In the context of diagnostic testing, it helps evaluate the body's response to corticosteroids, aiding in the differentiation between Cushing's syndrome and other conditions. Its specific properties make it a preferred choice in South Africa for this purpose, allowing physicians to assess cortisol levels and confirm the diagnosis accurately.

Fludrocortisone is a mineralocorticoid that promotes sodium retention and potassium excretion. Furosemide, a loop diuretic, enhances the excretion of potassium. When these two medications are used together, the potassium-wasting effects of furosemide can lead to significant hypokalaemia, which can cause serious cardiovascular complications. Therefore, monitoring potassium levels is crucial in patients taking both medications to prevent potential adverse effects.

In pediatric patients, the use of corticosteroids necessitates a careful evaluation of the benefit/risk ratio, particularly because these medications can lead to growth retardation. Children are still developing, and exposure to corticosteroids can interfere with their growth patterns. Therefore, it is crucial to weigh the therapeutic benefits of controlling severe asthma against the potential long-term consequences on growth and development. This consideration is paramount in pediatric prescribing, ensuring that treatment is both effective and safe for the child's overall health.